| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
167,290,000 |
| Market
Cap: |
31.79(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1872 - $0.8653 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,032 |
1,032 |
14,436 |
61,082 |
| Total Buy Value |
$2,561 |
$2,561 |
$7,159 |
$51,688 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
2 |
4 |
| Total Shares Sold |
0 |
214,287 |
906,546 |
1,224,952 |
| Total Sell Value |
$0 |
$97,285 |
$476,096 |
$787,968 |
| Total People Sold |
0 |
5 |
6 |
7 |
| Total Sell Transactions |
0 |
5 |
13 |
23 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wyzga Michael S |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
5,555 |
|
- |
|
| Stewart Murray |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
7,883 |
|
- |
|
| Bridger Gary |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,722 |
|
- |
|
| De Craecker Francoise |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,722 |
|
- |
|
| Mcgirr David W J |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,722 |
|
- |
|
| Woods Keith |
Director |
– • – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
6,000 |
|
- |
|
| Thoren Natasha Fay |
Chief Legal Officer |
• – – |
2025-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,333 |
9,462 |
|
- |
|
| Thoren Natasha Fay |
Chief Legal OfficerOfficer |
• – – |
2025-05-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,984 |
|
- |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2025-05-16 |
4/A |
A |
$2.48 |
$2,561 |
D/D |
1,032 |
25,337 |
|
- |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2025-05-16 |
4 |
B |
$2.48 |
$2,561 |
D/D |
1,032 |
25,337 |
2.66 |
- |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2025-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
650,000 |
1,140,980 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2025-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
850,000 |
850,000 |
|
- |
|
| Arbet-Engels Christophe |
Chief Medical Officer |
• – – |
2025-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
850,000 |
864,207 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2025-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250,000 |
3,337,386 |
|
- |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2025-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
729,173 |
|
- |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2025-01-24 |
4 |
AS |
$0.45 |
$10,094 |
D/D |
(22,258) |
490,980 |
|
-60% |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2025-01-24 |
4 |
AS |
$0.45 |
$13,241 |
D/D |
(29,159) |
94,123 |
|
-60% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2025-01-24 |
4 |
AS |
$0.45 |
$33,947 |
D/D |
(74,773) |
0 |
|
-60% |
|
| Ragan Paula |
President and CEO |
• • – |
2025-01-24 |
4 |
AS |
$0.45 |
$34,719 |
D/D |
(76,473) |
1,087,386 |
|
-60% |
|
| Arbet-Engels Christophe |
Chief Medical Officer |
• – – |
2025-01-24 |
4 |
AS |
$0.45 |
$5,284 |
D/D |
(11,624) |
14,207 |
|
-60% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
61,178 |
513,238 |
|
- |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
74,773 |
123,282 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
74,773 |
74,773 |
|
- |
|
| Ragan Paula |
President and CEO |
• • – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
169,940 |
1,163,859 |
|
- |
|
| Arbet-Engels Christophe |
Chief Medical Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
25,831 |
25,831 |
|
- |
|
208 Records found
|
|
Page 1 of 9 |
|
|
